Clinical Pharmacokinetics

, Volume 17, Issue 2, pp 90–108 | Cite as

Recent Developments in the Study of the Effects of Cigarette Smoking on Clinical Pharmacokinetics and Clinical Pharmacodynamics

  • Lucinda G. Miller
Review Article Drug Disposition


With the ever-increasing population of cigarette smokers, the potential for cigarette smoke to affect drug therapy both pharmacokinetically and pharmacodynamically is significant. The overriding pharmacokinetic effect is increased drug metabolism through the induction of liver enzymes. The constituents of tobacco smoke, primarily nicotine, have their own pharmacological effects which may potentiate or antagonise the desired pharmacological effect of a particular drug, thereby affecting its efficacy. Furthermore, end-organ responsiveness may also be altered by tobacco. These latter 2 aspects constitute altered clinical pharmacodynamics.

Approximately 30 drugs have been evaluated in terms of cigarette smoking. Induction of liver enzymes has been shown to increase the metabolism of imipramine, meprobamate, oestrogens, pentazocine, phenylbutazone, theophylline and warfarin. Nicotine has been shown to inhibit diuresis, alter ulcer healing, impair subcutaneous absorption, affect protein binding and stimulate catecholamine release; these effects have been evaluated in terms of therapy with frusemide (furosemide), histamine H2-antagonists, insulin, lignocaine (lidocaine) and α-blockers, respectively. The interactions have not been correlated with clinical significance in all cases. Diminished end-organ responsiveness may account for reduced drowsiness in smokers receiving chlorpromazine and benzodiazepines, compared with non-smokers. Smoking has been associated with diminished pain tolerance, requiring increased dosages of morphine, pethidine (meperidine) and propoxyphene. Enzyme-inducers such as carbamazepine, Phenytoin and phenobarbitone appear to be minimally affected by cigarette smoke, perhaps because hepatic enzymes are already maximally stimulated. Codeine, corticosteroids and nortriptyline do not appear to be affected by cigarette smoke. The bioavailability of glutethimide is higher in smokers, but this has not been associated with greater efficacy. The effect of smoking on paracetamol (acetaminophen) has been variable, depending on the extent of smoking, and does not appear to be of clinical significance.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ahlsten G, Ewald U, Tuvemo T. Maternal smoking reduces prostacyclin formation in human umbilical arteries. Acta Obstetrica et Gynecologica Scandinavica 65: 645–649, 1986CrossRefGoogle Scholar
  2. Ali B, Kaur S, Kumar A, Bhargova KP. Comparative evaluation of stimulatory effects of oral tobacco and nicotine consumption on hepatic microsomal N-demethylations. Biochemical Pharmacology 29: 3087–3092, 1980PubMedCrossRefGoogle Scholar
  3. Andersson K, Siegel R, Fuxe K, Eneroth R. Intravenous infusions of nicotine induce very rapid and discrete reduction of hypothalamic catecholamine levels associated with increases of ACTH, vasopressin and prolactin secretion. Acta Physiologica Scandinavica 118: 35–40, 1983PubMedCrossRefGoogle Scholar
  4. Atallah YH, Dorough HW, Thorstenson JH. Nature and fate of insecticide residues inhaled by rats in cigarette smoke. Drug Metabolism and Disposition 3: 513–519, 1975PubMedGoogle Scholar
  5. Aubert JF, Burnier M, Weber B, Nussberger J, Blunner HR. Nicotine-induced release of vasopressin in the conscious rat: rate of opioid peptides and hemodynamic effects. Journal of Pharmacology and Experimental Therapeutics 243: 681–685, 1987PubMedGoogle Scholar
  6. Bachmann K, Shapiro R, Fulton R, Carroll FT, Sullican TJ. Smoking and warfarin disposition. Clinical Pharmacology and Therapeutics 25: 309–315, 1979PubMedGoogle Scholar
  7. Ballenger JC, Post RM. Carbamazepine in manic-depressive illness: a new treatment. American Journal Psychiatry 137: 782–790, 1986Google Scholar
  8. Bauerfeind P, Cilluffo T, Fimmel CJ, Emde C, von Ritter C, et al. Does smoking interfere with the effect of histamine H2-receptor antagonists on intragastric acidity in man? Gut 28: 549–556, 1987PubMedCrossRefGoogle Scholar
  9. Benedek IH, Blouin RA. Influence of smoking on serum protein composition and the protein binding of drugs. Journal of Pharmacy and Pharmacology 36: 214–216, 1984PubMedCrossRefGoogle Scholar
  10. Benetello P, Furlanut M, Pasqui L, Carmillo L, Perlotto N, et al. Absence of effect of cigarette smoking on serum concentrations of some anticonvulsants in epileptic patients. Clinical Pharmacokinetics 12: 302–304, 1987PubMedCrossRefGoogle Scholar
  11. Benowitz NL. Clinical pharmacology of nicotine. Annual Review of Medicine 37: 21–32, 1986PubMedCrossRefGoogle Scholar
  12. Benowitz NL, Jacob P, Jones RT, Rosenberg J. Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. Journal of Pharmacology and Experimental Therapeutics 221: 368–372, 1982PubMedGoogle Scholar
  13. Blum A. Strategies to reduce cigarette sales: excise taxes and beyond. Journal of the American Medical Association 224: 1049–1050, 1986CrossRefGoogle Scholar
  14. Bock KW, Wiltfang J, Blume R, Ullrich D, Bricher J. Paracetamol as a test drug to determine glucuronide formation in man. Effects of inducers and of smoking. European Journal of Clinical Pharmacology 31: 677–683, 1987PubMedCrossRefGoogle Scholar
  15. Boston Collaborative Drug Surveillance Program. Decreased clinical efficacy of propoxyphene in cigarette smokers. Clinical Pharmacology and Therapeutics 14: 259–263, 1973Google Scholar
  16. Boyer WF, Lake CR. Initial severity and diagnosis influence the relationship of tricyclic plasma levels to response: a statistical response. Journal of Clinical Psychopharmacology 7: 67–71, 1987PubMedGoogle Scholar
  17. Bridbord K, Finklea JF, Wagoner JK, Moran JB, Caplan P. Human exposure to polynuclear aromatic hydrocarbons. In Freudenthal & Jones (Eds) Carcinogenesis. Polynuclear aromatic hydrocarbons: chemistry, metabolism and carcinogenesis, pp. 319–324, Raven Press, New York, 1976Google Scholar
  18. Brodsky L. Can nicotine control panic attacks? American Journal of Psychiatry 142: 524, 1985PubMedGoogle Scholar
  19. Bull HA, Pittilo RM, Woolf N, Machin SJ. The effect of smoking on human endothelial cell release of prostaglandins and ultra-structure. British Journal of Experimental Pathology 69: 413–421, 1988PubMedGoogle Scholar
  20. Chakrabarti AK, Sanantaray SK. Diabetic peripheral neuropathy: nerve conduction studies before, during and after carbamazepine therapy. Australian and New Zealand Journal of Medicine 6: 565–568, 1976PubMedCrossRefGoogle Scholar
  21. Cherck DR, Smith JE, Lane JD, Brauchi JT. Effects of cigarettes on saliva Cortisol levels. Clinical Pharmacology and Therapeutics 32: 7665–7668, 1982Google Scholar
  22. Cluette-Brown J, Mulligan J, Doyle K, Hogan S, Osmoloski T, et al. Oral nicotine induces an atherogenic lipoprotein profile. Proceedings of the Society for Experimental Biology and Medicine 182: 409–413, 1986PubMedGoogle Scholar
  23. Crow JW, Lovi P, Bochner F, Shoemen DW, Agarnoff DL. Glutethimide and 4-OH glutethimide: pharmacokinetics and effects on performance in man. Clinical Pharmacology and Therapeutics 22: 458–464, 1977PubMedGoogle Scholar
  24. Crowley JJ, Cusack BJ, Jue SG, Koup JR, Park BK, et al. Aging and drug interactions. II. Effect of Phenytoin and smoking on the oxidation of theophylline and Cortisol in healthy men. Journal of Pharmacology and Experimental Therapeutics 245: 513–523, 1988PubMedGoogle Scholar
  25. Cryer PE, Haymond MW, Santiago JV, Shah SD. Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. New England Journal of Medicine 295: 573–577, 1976PubMedCrossRefGoogle Scholar
  26. Cusack B, Dawson GW, Mercer GD, Vestal RE. Cigarette smoking and theophylline metabolism: effects of Cimetidine. Clinical Pharmacology and Therapeutics 37: 330–336, 1985PubMedCrossRefGoogle Scholar
  27. Cussack B, Kelly JG, Lavan J, O’Malley K. Theophylline kinetics in relation to age: the importance of smoking. British Journal of Clinical Pharmacology 10: 109–114, 1980CrossRefGoogle Scholar
  28. Davis D, Grossman SH, Kitchell BB, Stand DG, Routledge PA. The effects of age and smoking on the plasma protein binding of lignocaine and diazepam. British Journal of Clinical Pharmacology 19: 261–265, 1985PubMedCrossRefGoogle Scholar
  29. Dawson GW, Vestal RE. Smoking and drug metabolism. Pharmacology and Therapeutics 15: 207–221, 1982CrossRefGoogle Scholar
  30. Desmond DV, Roberts RK, Wilkinson GR, Schenker S. No effect of smoking on metabolism of chlordiazepoxide. New England Journal of Medicine 300: 1199–1200, 1979Google Scholar
  31. Domino EF. Nicotine: a unique psychoactive drug-arousal with skeletal muscle relaxation. Psychopharmacology Bulletin 22: 870–874, 1986PubMedGoogle Scholar
  32. Domschke S, Domschke W. Gastroduodenal damage due to drugs, alcohol and smoking. Clinics in Gastroenterology 13: 405–436, 1984PubMedGoogle Scholar
  33. Frankl WS, Soloff LA. The hemodynamic effects of propranolol hydrochloride after smoking. American Journal of the Medical Sciences 254: 623–628, 1967PubMedCrossRefGoogle Scholar
  34. Friedman GD, Siegelaub AB, Seltzer CC. Cigarettes, alcohol, coffee and peptic ulcer. New England Journal of Medicine 290: 469–473, 1974PubMedCrossRefGoogle Scholar
  35. Garg SK, Ravi KTN. Effect of smoking on phenylbutazone disposition. International Journal of Clinical Pharmacology, Therapy and Toxicology 29: 289–290, 1982Google Scholar
  36. Garnett WR. Sucralfate: alternative therapy for peptic ulcer disease. Clinical Pharmacy 1: 307–314, 1982PubMedGoogle Scholar
  37. Glauser SC, Glauser EM, Reidenberg MM, Rusy BR, Tallarida RJ. Metabolic changes associated with the cessation of cigarette smoking. Archives of Environmental Health 29: 377–381, 1970Google Scholar
  38. Godwin-Austen RB, Lee PN, Marnot MG, Stern GM. Smoking and Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry 45: 577–581, 1982CrossRefGoogle Scholar
  39. Grunberg NE. Nicotine, cigarette smoking, and body weight. British Journal of Addiction 80: 369–377, 1985PubMedCrossRefGoogle Scholar
  40. Grunberg NE. Nicotine as a psychoactive drug: appetite regulation. Psychopharmacology Bulletin 22: 875–881, 1986PubMedGoogle Scholar
  41. Grunberg NE, Bowon DJ, Maycock VA, Mespar SM. The importance of sweet taste and caloric content in the effects of nicotine on specific food consumption. Psychopharmacology 18: 198–203, 1985CrossRefGoogle Scholar
  42. Grunberg NE, Popp KA, Bowen DJ, Nespor SM, Sinders SE, et al. Effects of chronic nicotine administration on insulin, glucose, epinephrine, and norepinephrine. Life Sciences 42: 161–170, 1988PubMedCrossRefGoogle Scholar
  43. Gugler R, Rohner HG, Kratochvil P, Brandstatter G, Schmitz H. Effect of smoking on duodenal ulcer healing with Cimetidine and oxmetidine. Gut 23: 866–871, 1982PubMedCrossRefGoogle Scholar
  44. Hadley WM, Miya TS, Bousquet WF. Cadmium inhibition of hepatic drug metabolism in rat. Toxicology and Applied Pharmacology 28: 284–291, 1974PubMedCrossRefGoogle Scholar
  45. Hallerback B, Solhaug JH, Carling L, Glise H, Hallgren T, et al. Recurrent ulcer after treatment with Cimetidine of sucralfate. Scandinavian Journal of Gastroenterology 22: 791–797, 1987PubMedCrossRefGoogle Scholar
  46. Hisaoka M, Levy G. Kinetics of drug action in disease states XI: effect of nicotine on the pharmacodynamics and pharmacokinetics of phenobarbital and ethanol in rats. Journal of Pharmaceutical Sciences 74: 412–415, 1985PubMedCrossRefGoogle Scholar
  47. Hitzenberger G, Fitscha P, Beverdige T, Nuesche E, Pacha W. Effects of age and smoking on the pharmacokinetics of pindolol and propranolol. British Journal of Clinical Pharmacology 13 (Suppl. 2): 217S–222S, 1982aPubMedCrossRefGoogle Scholar
  48. Hitzenberger G, Fitscha P, Beverdige T, Nuesche E, Pacha W. Influence of smoking and age on pharmacokinetics of beta-receptor blockers. Gerontology 28 (Suppl. 1): 93–100, 1982bPubMedCrossRefGoogle Scholar
  49. Hojnacki J, Mulligan J, Cluette-Brown J, Joe F, Osmolski T. Oral nicotine impairs clearance of plasma low density lipoproteins. Proceedings of the Society for Experimental Biology and Medicine 182: 414–418, 1986PubMedGoogle Scholar
  50. Hughes JR. Nicotine gum to treat panic attacks. American Journal of Psychiatry 143: 371, 1986Google Scholar
  51. Hull JH, Findlay JW, Rogers JF, Welch RM, Butz RF, et al. An evaluation of the effects of smoking on codeine pharmacokinetics and bioavailability in normal human volunteers. Drug Intelligence and Clinical Pharmacy 16: 849–854, 1982PubMedGoogle Scholar
  52. Hunt SN, Jusko WJ, Yurchak AM. Effect of smoking on theophylline disposition. Clinical Pharmacology and Therapeutics 19: 546–551, 1976PubMedGoogle Scholar
  53. Jellinck PH, Krey L, Davis PG, et. al. Central and peripheral action of estradiol and catecholestrogens administered at low concentration by constant infusion. Endocrinology 108: 1848–1854, 1981PubMedCrossRefGoogle Scholar
  54. Jenne J, Nagasawa H, McHugh R, McDonald F, Wyse E. Decreased theophylline half-life in cigarette smokers. Life Sciences 17: 195–198, 1975PubMedCrossRefGoogle Scholar
  55. Jeremy JY, Mikhailidis DP, Dandona P. Cigarette smoke extracts, but not nicotine, inhibit prostacyclin (PGI2) synthesis in human, rabbit and rat vascular tissue. Prostaglandins, Leukotrienes and Medicine 19: 261–270, 1985CrossRefGoogle Scholar
  56. Jick H, Slone D, Shapiro S, et. al. Clinical depression of the central nervous system due to diazepam and chlordiazepoxide in relation to cigarette smoking and age. New England Journal of Medicine 288: 277–280, 1973CrossRefGoogle Scholar
  57. Jusko WJ. Role of tobacco smoking in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 6: 7–39, 1978PubMedGoogle Scholar
  58. Jusko WJ. Influence of cigarette smoking on drug metabolism in man. Drug Metabolism Reviews 9: 221–236, 1979PubMedCrossRefGoogle Scholar
  59. Jusko WJ, Schentag JJ, Clark JH, Gardner M, Yurchak AM. Enhanced biotransformation of theophylline in marijuana and tobacco smokers. Clinical Pharmacology and Therapeutics 24: 406–410, 1978Google Scholar
  60. Lam SK, Hui WM, Lau WY, Branicki FJH, Lai CL, et al. Sucralfate overcomes adverse effect of cigarette smoking on duodenal ulcer healing and prolongs subsequent remission. Gastroenterology 92: 1193–1201, 1987PubMedGoogle Scholar
  61. Lane MR, Lee SP. Recurrence of duodenal ulcer after medical treatment. Lancet 1: 1147–1149, 1988PubMedCrossRefGoogle Scholar
  62. Lee BL, Benowitz NL, Jacob P. Cigarette abstinence, nicotine gum and theophylline disposition. Annals of Internal Medicine 106: 553–555, 1987PubMedGoogle Scholar
  63. Kaplan NM. Strategies to reduce risks factors in hypertensive patients who smoke. American Heart Journal 115: 288–294, 1988PubMedCrossRefGoogle Scholar
  64. Kershbaum A, Pappajohn DJ, Bellet S, Hivabayashi M, Shafiha H. Effect of smoking and nicotine on adrenocortical secretion. Journal of the American Medical Association 203: 275–278, 1968PubMedCrossRefGoogle Scholar
  65. Kilburn KH. Effects of tobacco smoke on biological systems. Scandinavian Journal of the Respiratory Diseases (Suppl.) 91: 63–78, 1974Google Scholar
  66. Klein LW, Ambrose J, Plichard A, Holt J, Gorlin R, et al. Acute effects of cigarette smoking on coronary vascular dynamics. Circulation 68: 165, 1983Google Scholar
  67. Klemp P, Staberg B, Gadsbad S, Kolandorf K. Smoking reduces insulin absorption from subcutaneous tissue. British Medical Journal 284: 237, 1982PubMedCrossRefGoogle Scholar
  68. Korman MG, Hansky J, Merrett AC, Schmidt GT. Ranitidine in duodenal ulcer: healing rate and effect of smoking. Digestive Diseases and Sciences 27: 712–715, 1982PubMedCrossRefGoogle Scholar
  69. Kyerematen GA, Gamiano MD, Dvorchik BH, Vesell ES. Smoking-induced changes in nicotine disposition: application of a new HPLC assay for nicotine and its metabolites. Clinical Pharmacology and Therapeutics 32: 769–780, 1982PubMedCrossRefGoogle Scholar
  70. Lambert C, Larochelle P, duSouch P. Effects of phenobarbital and tobacco smoking on furosemide kinetics and dynamics in normal subjects. Clinical Pharmacology and Therapeutics 34: 170–175, 1983PubMedCrossRefGoogle Scholar
  71. Lichtensteiger W, Hefti F, Felix D, Huwyler T, Melamed E, et al. Stimulation of nigrostriatal dopamine neurons by nicotine. Neuropharmacology 21: 963–968, 1982PubMedCrossRefGoogle Scholar
  72. Luczynska C, Wilson K. The clinical significance of the effects of cigarette smoking on drug disposition. Methods and Findings in Experiments and Clinical Pharmacology 5: 474–487, 1983Google Scholar
  73. Maany I, Woody G, Foulks E. Nicotine and panic attacks. American Journal of Psychiatry 144: 255, 1987PubMedGoogle Scholar
  74. Madsbad S, McHair P, Christensen MS, et al. Influence of smoking on insulin requirement and metabolic status in diabetes mellitus. Diabetes Care 3: 41–43, 1980PubMedCrossRefGoogle Scholar
  75. Mather LE, Tucker GT, Pflug AE, Lindop MJ, Wilkerson C. Meperidine kinetics in man: intravenous injection in surgical patients and volunteers. Clinical Pharmacology and Therapeutics 17: 21–30, 1975PubMedGoogle Scholar
  76. Mathiesen ER, Segaard U, Christiansen JS. Smoking and glycemic control in male insulin dependent (Type I) diabetics. Diabetes Research 1: 155–157, 1984PubMedGoogle Scholar
  77. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, Phenytoin and primidone in partial and secondarily generalized tonic-clonic seizures. New England Journal of Medicine 313: 145–151, 1985PubMedCrossRefGoogle Scholar
  78. McCormick A, Nicholson MJ, Baylis MA, Underwood JG. Nitrosamines in cigarette smoke condensate. Nature 244: 237–238, 1973PubMedCrossRefGoogle Scholar
  79. McNamara PJ, Slaugher RL, Visco JP, Elwood CM, Siegel JH, et al. Effect of smoking on binding of lidocaine to human serum proteins. Journal of Pharmaceutical Sciences 69: 749–751, 1980PubMedCrossRefGoogle Scholar
  80. Michnovicz JJ, Herschcopf RJ, Naganuma H, Bradlow HL, Fishman J. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. New England Journal of Medicine 315: 1305–1309, 1986PubMedCrossRefGoogle Scholar
  81. Miller LG. Choice of beta blockers in hypertensive patients who smoke. Clinical Pharmacy 6: 924–925, 1987PubMedGoogle Scholar
  82. Miller LG, Jankovic J. Drug-induced movement disorders: an overview. In Joseph & Young (Eds) Movement disorders in psychiatry and neurology, Blackwell Scientific Publishers Inc, Boston, in press, 1989Google Scholar
  83. Miller LG, Prichard JG. Selecting nonsteroidal anti-inflammatory drugs: pharmacologic and clinical considerations. Journal of the American Board of Family Practice, in press, 1989Google Scholar
  84. Miller RR. Effects of smoking on drug action. Clinical Pharmacology and Therapeutics 22: 749–756, 1977PubMedGoogle Scholar
  85. Miners JO, Attwood J, Birkett DJ. Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism and acetaminophen’s metabolic pathways. Clinical Pharmacology and Therapeutics 35: 480–486, 1984PubMedCrossRefGoogle Scholar
  86. Murdock HR, Robillard NF. Use of smokers in bioavailability studies. Clinical Pharmacology and Therapeutics 24: 23, 1979Google Scholar
  87. Nadler JL, Velasco JS, Horton R. Cigarette smoking inhibits prostacyclin formation. Lancet 1: 1248–1250, 1983PubMedCrossRefGoogle Scholar
  88. Norman TR, Burrows GD, Maguire KP, Rubinstein G, Scoggins BA, et al. Cigarette smoking and plasma nortriptyline levels. Clinical Pharmacology and Therapeutics 122: 453–456, 1977Google Scholar
  89. Norman TR, Fulton A, Burrows GD, Maguire KP. Pharmacokinetics of N-desmethyldiazepam after a single oral dose of clorazepate: the effect of smoking. European Journal of Clinical Pharmacology 21: 229–233, 1981PubMedCrossRefGoogle Scholar
  90. Ochs HR, Greenblatt DJ, Knuchel M. Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. Chest 87: 223–226, 1985PubMedCrossRefGoogle Scholar
  91. Ochs HR, Greenblatt DJ, Locniskar A, Weinbrenner J. Influence of propranolol coadministration on cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. Klinische Wochenschrift 64: 1217–1221, 1986PubMedCrossRefGoogle Scholar
  92. Ochs HR, Greenblatt DJ, Otten H. Disposition of oxazepam in relation to age, sex and cigarette smoking. Klinische Wochenschrift 59: 889–903, 1981PubMedCrossRefGoogle Scholar
  93. Perel JM, Hurwic MJ, Kanzler MB. Pharmacodynamics of imipramine in depressed patients. Psychopharmacology Bulletin 11: 16–18, 1975PubMedGoogle Scholar
  94. Pomerlau OF. Nicotine as a psychoactive drug: anxiety and pain reduction. Psychopharmacology Bulletin 22: 865–869, 1986Google Scholar
  95. Powell JR, Thiercelin JF, Vozek S, Sansom L, Rugelman S. The influence of cigarette smoking and sex on theophylline disposition. American Review of Respiratory Disease 116: 17–23, 1977PubMedGoogle Scholar
  96. Queneau P, Ollagneir M, Decoutsus H, Perpoint B, Brazier JL, et al. Influence of tobacco on the serum levels and pharmacokinetics of phenylbutazone and oxyphenbutazone. Revue du Rhumatisme et des Maladies Ostéo-Articulaires, 59: 293–307, 1983Google Scholar
  97. Rigal JG, Albin H, Cuchier AR, D’Aulnay JM, Fenelon JH, et al. Imipramine blood levels and clinical outcome. Journal of Clinical Psychopharmacology 7: 222–229, 1987PubMedCrossRefGoogle Scholar
  98. Rodin J, Wack J, Ferrannini E, DeFronzo RA. Effect of insulin and glucose on feeding behavior. Metabolism 35: 826–831, 1985CrossRefGoogle Scholar
  99. Rogers JF, Findlay JW, Hull JH, Butz RF, Jones EC, et al. Codeine disposition in smokers and nonsmokers. Clinical Pharmacology and Therapeutics 32: 218–227, 1982PubMedCrossRefGoogle Scholar
  100. Rondia D. Abaissement de l’activité de la benzopyrene hydroxylase hépatique in vivo après inhalation d’oxyde de carbone. Comptes Rendues de l’Academie des Sciences 271: 617–619, 1970Google Scholar
  101. Rose JQ, Yurchak AM, Meikle AW, Jusko WJ. Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 9: 1–14, 1981PubMedGoogle Scholar
  102. Seltzer CC, Friedman GD, Seigelaub AB, Collen MF. Smoking habits and pain tolerance. Archives of Environmental Health 29: 170–172, 1974PubMedGoogle Scholar
  103. Sershen H, Hashim A, Laj-tha A. Behavioral and biochemical effects of nicotine in an MPTP-induced mouse model of Parkinson’s disease. Pharmacology, Biochemistry and Behaviour 28: 299–303, 1987CrossRefGoogle Scholar
  104. Sershen H, Mosem MG, Reith MEA, Hashim A, Lajtha A. Effect of nicotine and amphetamine on the neurotoxicity of N-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) in mice. Neuropharmacology 11: 1231–1234, 1986CrossRefGoogle Scholar
  105. Severson RF, Snook ME, Ariendale RF, Chortyk OT. Gas chromatographic quantitation of polynuclear aromatic hydrocarbons in tobacco smoke. Analytical Chemistry 48: 1866–1872, 1976PubMedCrossRefGoogle Scholar
  106. Stimmel GL, Falloon IR. Chlorpromazine plasma levels, adverse effects and tobacco smoking: case report. Journal of Clinical Psychiatry 44: 420–422, 1983PubMedGoogle Scholar
  107. Summy-Long JY, Keil LC, Deen K, Severs WB. Opiate regulation of angiotensin-induced drinking and vasopressin release. Journal of Pharmacology and Experimental Therapeutics 217: 630–637, 1981PubMedGoogle Scholar
  108. Svensson CR. Clinical pharmacokinetics of nicotine. Clinical Pharmacokinetics 12: 30–40, 1987PubMedCrossRefGoogle Scholar
  109. Swett C. Drowsiness due to chlorpromazine in relation to cigarette smoking. Archives of General Psychiatry 31: 211–213, 1974PubMedCrossRefGoogle Scholar
  110. Taylor NBG, Walker JM. Antidiuretic substance in human urine after smoking. Journal of Physiology 113: 412–418, 1951PubMedGoogle Scholar
  111. Tomson T, Tybring G, Bertilsson L, Ekbom K, Rane A. Carbamazephine therapy in trigeminal neuralgia. Archives of Neurology 37: 699–703, 1980PubMedCrossRefGoogle Scholar
  112. Vapaatalo P, Neuvonen PJ, Tissari A, Mansner R, Paasonen MK. Effect of cigarette smoking on diuresis induced by furosemide. Annals of Clinical Research 3: 159–164, 1971PubMedGoogle Scholar
  113. Vaughan DP, Beckett AH. The influence of smoking on the intersubject variation in pentazocine elimination. British Journal of Clinical Pharmacology 3: 279–283, 1976PubMedCrossRefGoogle Scholar
  114. Vessey MP, Villard-Mackintosh L, Jacobs HS. Anti-estrogenic effect of cigarette smoking. New England Journal of Medicine 317: 769–770, 1987PubMedCrossRefGoogle Scholar
  115. Vestal RE, Cusack BJ, Mercer GD, Dawson SW, Park BK. Aging and drug interactions. I. Effect of Cimetidine and smoking on the oxidation of theophylline and Cortisol in healthy men. Journal of Pharmacology and Experimental Therapeutics 241: 488–500, 1987PubMedGoogle Scholar
  116. Weiner B, Faraci PA, Fayad R, Swanson L. Warfarin dosage following prosthetic valve replacement: effect of smoking history. Drug Intelligence and Clinical Pharmacy 18: 904–906, 1984.PubMedGoogle Scholar
  117. Wenzel DG, Broadie LL. Stimulatory effect of nicotine on the metabolism of meprobamate. Toxicology and Applied Pharmacology 8: 455–459, 1966PubMedCrossRefGoogle Scholar
  118. Winternitz WW, Quillen D. Acute hormonal response to cigarette smoking. Journal of Clinical Pharmacology 17: 389–397, 1977PubMedGoogle Scholar
  119. Yassa R, Lal S, Korpassy A, Ally J. Nicotine exposure and tardive dyskinesia. Biological Psychiatry 22: 67–72, 1987PubMedCrossRefGoogle Scholar

Copyright information

© ADIS Press Limited 1989

Authors and Affiliations

  • Lucinda G. Miller
    • 1
  1. 1.Department of Family MedicineBaylor College of MedicineHoustonUSA

Personalised recommendations